GlassScriptPhysician profile
Robert G Matheny
NPI 1225142557
$10,196.81
in general payments reported to CMS, 2019-2025
22 companies · $79.99 in 2025
The $79.99 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $149 · 2021: $336 · 2023: $328 · 2024: $8,332 · 2025: $79.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,060 · Travel and Lodging: $864 · Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,059.80 |
| Travel and Lodging | $864.03 |
| Food and Beverage | $815.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,137.98 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $585.79 | 2019-2024 | Tezspire |
| Philips North America LLC | $418.78 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $182.38 | 2019-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $158.47 | 2019-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.39 | 2019-2021 | |
| Mylan Specialty L.P. | $84.56 | 2019-2021 | |
| Glaxosmithkline, LLC. | $79.87 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $79.39 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Paratek Pharmaceuticals, INC. | $38.47 | 2021 | |
| Shire North American Group INC | $35.60 | 2019 | |
| Genzyme Corporation | $32.25 | 2019 | |
| Sunovion Pharmaceuticals INC. | $28.78 | 2019 | |
| Grifols USA, LLC | $25.54 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veran Medical Technologies, INC. | $24.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.19 | 2025 | Glassia |
| Zoll Respicardia, INC. | $19.26 | 2024 | Remede System |
| Merck Sharp & Dohme LLC | $18.75 | 2019 | |
| United Therapeutics Corporation | $16.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.66 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Matheny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.